Search Results
Feb 12, 2026, 09:01 ET Anterior Closes $40 Million to Accelerate Health Plan AI Adoption, Bringing Total Funding to $64 Million
Dr. Abdel Mahmoud, MD, Physician and former Google Product Leader and CEO at Anterior. "We built Anterior around a different premise: AI only works in healthcare when
More news about: Anterior
Feb 12, 2026, 09:00 ET Ally Services Completes Three Add-on Acquisitions in 2025, Expanding Residential HVAC Platform
ROCKVILLE, Md., Feb. 12, 2026 /PRNewswire/ -- Ally Services (
More news about: Ally Services
Feb 12, 2026, 09:00 ET Beta-Lactam Allergy Delabeling Safe for Pregnant Patients
and their safety. This research suggests that beta-lactam allergy evaluation in pregnancy reduces alternative antibiotic use," said Divya L. Jasthi, MD, MPH, primary author of the study.In this single-center retrospective study, researchers examined third trimester pregnant patients referred for
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 12, 2026, 09:00 ET Randomized Controlled Trial Demonstrated Positive Outcomes for FDA-Cleared Brain-Computer Interface IpsiHand® System in Chronic Stroke Rehabilitation
The results were presented by Eric C. Leuthardt, MD, MBA, during an oral abstract in the main event at ISC 2026. The abstract, "A randomized trial of an at-home brain-computer interface therapy compared
More news about: Kandu, Inc.
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
offers a new approach to treating gMG by selectively targeting CD19-positive B cells, which play a key role in disease pathology," said John Vissing, MD, DMSci, professor of neurology and director of the Copenhagen Neuromuscular Center, Rigshospitalet, at the University of Copenhagen. "The approval provides
More news about: Amgen
Feb 12, 2026, 08:32 ET rater8 Announces Winners of the 2025 Practice Excellence Awards
Carrie Wilcox, MD, Orthopedic Physician Associates, Seattle, WADaniel Wartinbee, MD, South Carolina Sports Medicine & Orthopaedic Center, North Charleston, SCJohn Bush, MD, FACOG, Midwest Center for Women's HealthCare, Bannockburn, ILManuel Martinez, MD, Gonzaba Medical
More news about: rater8
Feb 12, 2026, 08:00 ET Onkos Surgical® Announces Initiation of 522 Post-Market Surveillance Study of the ELEOS™ Limb Salvage System with NanoCept® Antibacterial Implant Technology
patients with malignant bone tumors that require limb reconstruction for maintenance of function as part of their cancer treatment," said Joel Mayerson, MD, orthopedic oncologist, director of the sarcoma program and chief of musculoskeletal oncology at The Ohio State University Comprehensive Cancer Center
More news about: ONKOS SURGICAL
Feb 12, 2026, 08:00 ET Inovalon Named Global Leaders Champion for Scaling ScriptMed® on Oracle AI Database to Power Pharmacy Operations
scalable transaction processing for specialty and infusion pharmacies managing complex therapiesBOWIE, Md., Feb. 12, 2026 /PRNewswire/ --
More news about: Inovalon
Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones
works.A clinical update was provided for the ongoing open-label, investigator-initiated study (IIS) sponsored by Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of
More news about: SOLIGENIX, INC.
Feb 12, 2026, 07:00 ET The Biological Computing Co. (TBC) Secures $25 Million Seed Round, First to Deploy Neuron-Based Alternative to Silicon AI
co-founder of Neuralink.Believing that better computers require a revolution in computing itself, TBC co-founders Alex Ksendsovsky, MD, PhD, and Jon Pomeraniec, MD, MBA, both neurosurgeon-neuroscientists, are establishing a new computing category where biological networks complement silicon to unlock
More news about: The Biological Computing Co.
Feb 12, 2026, 06:45 ET TELUS reports strong and industry leading operational and financial results for the fourth quarter and full year 2025; establishes compelling and industry-best 2026 financial targets
our 2025 annual MD&A. Our assumptions in support of our 2026 outlook are generally based on industry analysis, including our estimates regarding economic and telecom industry growth, as well as our 2025 results and trends discussed in Section 5 in our 2025 annual MD&A. Our 2026 key assumptions
More news about: TELUS Corporation
Feb 12, 2026, 06:45 ET TELUS reports strong and industry leading operational and financial results for the fourth quarter and full year 2025; establishes compelling and industry-best 2026 financial targets
our 2025 annual MD&A. Our assumptions in support of our 2026 outlook are generally based on industry analysis, including our estimates regarding economic and telecom industry growth, as well as our 2025 results and trends discussed in Section 5 in our 2025 annual MD&A. Our 2026 key assumptions
More news about: TELUS Corporation
Feb 11, 2026, 19:30 ET ORVANA ANNOUNCES Q1 FY2026 RESULTS; PROVIDES UPDATE OXIDES STOCKPILE PROJECT AND FY2026 GUIDANCE FOR BOLIVIA
prepared in accordance with IFRS. For further information, please see the "Non-GAAP Financial Performance Measures" section of the Company's Q1 FY2026 MD&A. (3)
More news about: Orvana Minerals Corp.
Feb 11, 2026, 18:32 ET NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2025
project.MANAGEMENT DISCUSSION AND ANALYSISThis news release should be read in conjunction with the Company's management discussion and analysis (the "MD&A") and the audited consolidated financial statements and notes thereto for the corresponding period, which have been filed with the Canadian Securities
More news about: New Pacific Metals Corp.
Feb 11, 2026, 18:16 ET Manulife files 2025 Audited Annual Financial Statements and Related MD&A
/PRNewswire/ - Manulife Financial Corporation has filed its 2025 audited annual financial statements for the year ended December 31, 2025 and related MD&A with securities regulators, including with the Canadian Securities Administrators and with the U.S. Securities and Exchange Commission on Form 40-F.
More news about: Manulife Financial Corporation
Feb 11, 2026, 18:16 ET Manulife files 2025 Audited Annual Financial Statements and Related MD&A
2026 /CNW/ - Manulife Financial Corporation has filed its 2025 audited annual financial statements for the year ended December 31, 2025 and related MD&A with securities regulators, including with the Canadian Securities Administrators and with the U.S. Securities and Exchange Commission on Form 40-F.
More news about: Manulife Financial Corporation
Feb 11, 2026, 17:30 ET WEST FRASER ANNOUNCES COMPLETION OF FORM 40-F FILING
Form 40-F includes the Company's audited financial statements for the year ended December 31, 2025, annual management's discussion and analysis ("MD&A") and annual information form, each of which have been filed with Canadian securities authorities on SEDAR+ (
More news about: West Fraser Timber Co. Ltd.
Feb 11, 2026, 17:02 ET Manulife Reports Full Year and Fourth Quarter 2025 Results
non-GAAP and other financial measures, see "Non-GAAP and other financial measures" below and in our 2025 Management's Discussion and Analysis ("2025 MD&A").(3)
More news about: Manulife Financial Corporation
Feb 11, 2026, 17:02 ET Manulife Reports Full Year and Fourth Quarter 2025 Results
non-GAAP and other financial measures, see "Non-GAAP and other financial measures" below and in our 2025 Management's Discussion and Analysis ("2025 MD&A").(3)
More news about: Manulife Financial Corporation
Feb 11, 2026, 17:01 ET West Fraser Announces Fourth Quarter 2025 Results
www.westfraser.com in the "Investors/Dividends" section.Management Discussion & Analysis ("MD&A") Our 2025 Annual MD&A and audited annual consolidated financial statements and accompanying notes are available on our website at
More news about: West Fraser Timber Co. Ltd.
Feb 11, 2026, 17:01 ET Sun Life Reports Fourth Quarter and Full Year 2025 Results
see section H - Non-IFRS Financial Measures in this document and in our Management's Discussion and Analysis ("MD&A") for the period ended December 31, 2025 ("2025 Annual MD&A").(2)
More news about: Sun Life Financial Inc. - Financial News
Feb 11, 2026, 17:01 ET Sun Life Reports Fourth Quarter and Full Year 2025 Results
see section H - Non-IFRS Financial Measures in this document and in our Management's Discussion and Analysis ("MD&A") for the period ended December 31, 2025 ("2025 Annual MD&A").(2)
More news about: Sun Life Financial Inc. - Financial News
Feb 11, 2026, 17:01 ET RUSSEL METALS ANNOUNCES 2025 ANNUAL & FOURTH QUARTER RESULTS
those anticipated in our forward-looking statements including as a result of the risk factors described above and under the heading "Risk" in our MD&A and under the heading "Risk Management and Risks Affecting Our Business" in our most recent Annual Information Form and as otherwise disclosed in
More news about: Russel Metals Inc.
Feb 11, 2026, 16:01 ET AGNC Investment Corp. Declares Monthly Common Stock Dividend of $0.12 per Common Share for February 2026
BETHESDA, Md., Feb. 11, 2026 /PRNewswire/ -- AGNC Investment Corp. (Nasdaq: AGNC) announced today that its Board of Directors has declared a cash dividend of $0.12 per share of common stock for February 2026. The dividend is
More news about: AGNC Investment Corp.
Feb 11, 2026, 16:00 ET Barzolvolimab Provides Long-Term Improvements for Spontaneous Urticaria
response, no itch or hives, at 12 weeks which continued to deepen over 52 weeks of treatment to up to 71% of patients," said lead author Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)